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Abstract
Promyelocytic leukemia-retinoic acid receptor alpha (PML-RARa) expression in acute promyelocytic leukemia (APL) impairs
transforming growth factor beta (TGFb) signaling, leading to cell growth advantage. Halofuginone (HF), a low-molecular-
weight alkaloid that modulates TGFb signaling, was used to treat APL cell lines and non-obese diabetic/severe combined
immunodeficiency (NOD/SCID) mice subjected to transplantation with leukemic cells from human chorionic gonadotrophin-
PML-RARa transgenic mice (TG). Cell cycle analysis using incorporated bromodeoxyuridine and 7-amino-actinomycin D
showed that, in NB4 and NB4-R2 APL cell lines, HF inhibited cellular proliferation (P,0.001) and induced apoptosis
(P=0.002) after a 24-hour incubation. Addition of TGFb revealed that NB4 cells were resistant to its growth-suppressive
effects and that HF induced these effects in the presence or absence of the cytokine. Cell growth inhibition was associated
with up-regulation of TGFb target genes involved in cell cycle regulation (TGFB, TGFBRI, SMAD3, p15, and p21) and down-
regulation of MYC. Additionally, TGFb protein levels were decreased in leukemic TG animals and HF in vivo could restore
TGFb values to normal. To test the in vivo anti-leukemic activity of HF, we transplanted NOD/SCID mice with TG leukemic
cells and treated them with HF for 21 days. HF induced partial hematological remission in the peripheral blood, bone
marrow, and spleen. Together, these results suggest that HF has anti-proliferative and anti-leukemic effects by reversing the
TGFb blockade in APL. Since loss of the TGFb response in leukemic cells may be an important second oncogenic hit,
modulation of TGFb signaling may be of therapeutic interest.
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Introduction
Transforming growth factor beta (TGFb) is a cytokine that
regulates multiple cellular responses, including inhibition of cell
proliferation and induction of differentiation, senescence, and
apoptosis [1,2]. Its actions are mediated by binding to the serine/
threonine kinase receptor TbRII that recruits and activates TbRI,
which in turn phosphorylates downstream targets. These include
the proteins SMAD2 and SMAD3, which translocate to the
nucleus in a complex with the common mediator SMAD4 to
regulate transcription of target genes [3,4]. The tumor suppressor
responses of TGFb are essential for maintaining homeostatic
control of normal cell growth and cells in the early phases of
tumorigenesis. Among the TGFb-mediated effects in premalignant
cells are the suppression of c-Myc expression [5] and the induction
of the cell cycle inhibitors p15 and p21. Although these actions
imply a tumor suppressor role for TGFb, its effects are both cell-
and context-dependent. In that regard, Siegel et al. have shown
that activation of TGFb delays the appearance of primary
mammary tumors, and mice deficient in TGFb signaling are
prone to earlier tumor development, suggesting that the tumor
suppressor response of TGFb is important in the early stages of
tumorigenesis. In contrast, mice expressing an activated TGFb
receptor exhibited increased metastatic lung foci, consistent with a
pro-oncogenic effect of this pathway in late-stage disease [6]. In
addition, advanced disease is accompanied by increased expres-
sion and activation of the ligand but decreased TGFb responsive-
ness, thus facilitating tumor cell growth [7].
Deregulation of TGFb signaling may alter hematopoiesis,
causing a predisposition to leukemia. In contrast to solid tumors,
mutations in SMAD genes are rare in leukemia and disruption of
TGFb responsiveness is commonly secondary to either (a) altered
transcription, as described in acute myeloid leukemia with
translocation t(8;21), in which the AML1/ETO chimeric protein
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26713represses transcription of TGFb-responsive genes [8] or (b)
disruption of TGFb target gene expression such as the cell cycle
regulators c-Myc, p15 and p21, which are commonly associated
with leukemogenesis [9].
The role of TGFb in leukemogenesis has been recently studied
in acute promyelocytic leukemia (APL), a distinct subtype of acute
myeloid leukemia (AML) associated with t(15;17) and expression of
the promyelocytic leukemia-retinoic acid receptor alpha (PML-
RARa) hybrid protein. A gene expression study using microarrays
has revealed that TGFb was downregulated in APL compared
with most non-APL samples [10]. In contrast, Raza et al. have
described elevated TGFb protein expression by immunohisto-
chemistry in bone marrow biopsies of 23 APL patients [11]. Lin
et al. have demonstrated that the cytoplasmic isoform of PML
(cPML) is essential for TGFb signaling and Pml-null primary cells
are resistant to TGFb-dependent growth arrest, induction of
cellular senescence, apoptosis, phosphorylation of Smad2/3, and
induction of p15 and p21 expression. Restoration of cPML fully
rescued these defects [12]. Since cPML function is impaired in
APL blasts, through the formation of cPML/PML-RARa
heterodimers, the authors hypothesized that this would be the
molecular mechanism of resistance to TGFb anti-proliferative
responses [13].
To better characterize the deregulation of the TGFb pathway in
APL and to determine its potential as a therapeutic target, we took
advantage of the human chorionic gonadotrophin (hCG)-PML/
RARa transgenic model and analyzed the effects of halofuginone
(HF; dl-trans-7-bromo-6-chloro-3-[3-(3-hydroxy-2piperidyl)aceto-
nyl]-4(3H)-quinazolinone hydrobromide), which is a low-molecu-
lar-weight alkaloid that has been shown to modulate TGFb
signaling. In several cultured cell lines, this drug decreased TGFb-
induced phosphorylation of SMADs 2 and 3 and induced
expression of inhibitory SMAD7 mRNA [14]. HF also reduced
tumor growth in in vivo models of pheochromocytoma [15], brain
tumors [16], and hepatocellular carcinoma [17]. The effects of HF
in hematopoietic malignancies have not been previously described.
Our results demonstrate that HF treatment induces anti-prolifer-
ative and pro-apoptotic effects, up-regulates TGFb target gene
expression, and significantly reduces the leukemic burden in vivo.
Materials and Methods
Ethics Statement
This study was approved by the Research Ethics Committee of the
University Hospital of the Medical School of Ribeira ˜o Preto, University of Sa ˜o
Paulo, process number 3865/2005). Experiments using mice were
conducted according to national guidelines for the care and use of
laboratory animals (Brazilian College of Animal Experimentation) and
was approved by the institutional Animal Experimentation Ethics
Committee (protocol number 088/2007).
Cell culture
NB4, a permanent cell line harboring t(15;17) [18], and its
derivative NB4-R2, in which all-trans retinoic acid (ATRA)-
unresponsiveness is associated with a point mutation in the
retinoid-binding domain of PML-RARa [19], were used for in vitro
assays. Cells were cultured in RPMI 1640 with 10% heat-
inactivated fetal calf serum (FCS; Gibco BRL, UK) and
maintained at 37uCi naC O 2-humidified incubator.
Treatment of APL cell lines with HF
HF was kindly provided by Prof. Arnon Nagler (Chaim Sheba
Medical Center, Tel Hashomer, Israel). Stock solutions of 1 mg/
mL were kept at 280uC until use. Subsequently, working solutions
of 10 ng/mL were freshly prepared by diluting the stock solution
with autoclaved water (for cell culture assays) or 0.9% NaCl (for in
vivo studies).
Cell suspensions containing 5610
5 cells/mL of culture were
treated with increasing doses of HF (6.25–200 ng/mL), which was
directly added to the medium, and then cells were harvested after
24, 48, or 72 hours of incubation as indicated. Cell viability
measurements were recorded with an initial minimum viability of
at least 95% as determined by the Trypan blue assay. For cell cycle
analysis and gene expression studies, NB4 cells were also subjected
to concurrent treatment with TGFb (0.5 ng/mL; Sigma-Aldrich,
St. Louis, MO, EUA) as indicated.
Cell proliferation and apoptosis assays
For the analysis of proliferation and the cell cycle, NB4 and
NB4-R2 cells were treated with HF as described above for
24 hours and then were subjected to immunofluorescent staining
of incorporated bromodeoxyuridine (BrdU) and 7-amino-actino-
mycin (7-AAD), followed by flow cytometric analysis using the
BrdU Flow Kit (BD Biosciences, San Jose, CA, USA). In this
method, BrdU, an analog of the DNA precursor thymidine, is
incorporated into newly synthesized DNA by cells entering and
progressing through the S (DNA synthesis) phase of the cell cycle.
The incorporated BrdU is stained with a specific BrdU
allophycocyanin (APC)-conjugated antibody and 7-amino-actino-
mycin (7-AAD), a dye that binds to total DNA. With this
combination, a two-color flow cytometric analysis permits the
enumeration and characterization of cells that are actively
synthesizing DNA (BrdU incorporation) according to their cell
cycle position (i.e., G0/1, S, or G2/M phases defined by 7-AAD
staining intensities). Cells were incubated with 10 mM of BrdU
during the last 30 minutes of culture, and then processed
according to the manufacturer’s recommendations. For the NB4
cell line only, TGFb was added or not to the culture medium to
evaluate the tumor suppressive effects of TGFb.
For the analysis of apoptosis after 24 and 48 hours of HF
treatment, NB4 cells that were treated with different concentra-
tions of HF were evaluated using the Trypan blue exclusion assay.
Concomitantly, apoptosis was determined using the Annexin V
and propidium iodide (PI) binding assay (BD Biosciences), and
then analyzed by flow cytometry. Each sample was washed in 16
phosphate-buffered saline (PBS), and then incubated with 5 mLo f
Annexin V, 5 mL of PI, or both at 4uC for 15 min. Subsequently,
400 mL of binding buffer was added to the samples.
All experiments were performed in triplicate and in each
sample, 10,000 events were acquired in a FACSCalibur flow
cytometer (BD Biosciences) and analysis was performed using Cell
Quest software.
The effective dose at 50% (ED50) of HF was calculated based on
the inhibition of proliferation in the NB4 cell line as determined by
the BrdU incorporation assay. This analysis was performed using
CalcuSyn software (Biosoft, Great Shelford, UK).
Analysis of TGFb target gene expression by real-time
polymerase chain reaction (PCR)
NB4 and NB4-R2 cells were treated as above for 24 or
72 hours, and wherever indicated, TGFb (0.5 ng/mL) was added
1 hour before HF to the culture. Total RNA was isolated using
Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Reverse transcription of 500 ng of
RNA was performed using the cDNA High Capacity Archive kit
(Applied Biosystems, Foster City, CA, USA). Subsequently, the
mRNA expression of TGFb target genes that are involved in cell
cycle regulation (TGFB, TGFBRI, p15, p21, SMAD3, and MYC) was
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cDNA samples were diluted five times and were processed in
duplicate.The PCRamplification was performed in 40 cycles,using
the Taqman PCR master mix, in an SDS (Sequence Detection
System) 5700 plataform connected to a 7300 Real-Time PCR
System (Applied Biosystems). The probes used for amplification
were synthesized using the Assay-on-Demand System (Applied
Biosystems) with the following GeneBank sequences: TGFb
(NM_003236, FAM-TGAACCAAGGAGACGGAATACAGGG-
NFQ), TGFbRI (NM_004612.2, FAM-TGGCAGAGCTGT-
GAAGCCTTGAGAG-NFQ), SMAD3 (NM_005902.3, FAM-
GGGAGCGGAGTACAGGAGACAGACT-NFQ), p15 (NM_
006428.3, FAM-CCAACAACGACAAGCTCTCCAAGAG-NFQ),
p21 (NM_000389.2, FAM-GGCAGACCAGCATGACAGATTTC-
TA-NFQ), and MYC (NM_002467.3, FAM-AACCAGCAGCCT-
CCCGCGACGATGC-NFQ). The expression of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping gene was determined
using the PDAR reagent (Pre-Developed Assay Reagent; Applied
Biosystems) and was used to normalize the data. The 2
2DDCT method
was used in the analysis of the PCR data and the relative gene
expression in a particular sample was determined as follows: relative
amount of target=2
2DDCT value.
Detection of TGFb protein expression
After treatment with HF as described above, total protein
extracts were obtained according to Schreiber et al. [20]. Briefly,
NB4 cells were washed twice in cold PBS, lysed with lysis buffer
(20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA,
1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b- glycero-
phosphate, 1 mM Na3VO4, 1 mg/mL leupeptin) containing a
protease inhibitor mixture P8340 (Sigma, St. Louis, MO, USA)
and homogenized in a Dounce system (model D-130, Biosystems,
Brazil) for one minute on ice. Lysates were centrifuged at 20,0006
g for 30 minutes at 4uC and the supernatants were removed.
Protein concentration was determined by the Bradford’s method
[21]. Proteins were submitted to SDS–PAGE and a total of 30 mg
of protein from each sample was transferred to polyvinylidene
fluoride (PVDF) membranes (GE Lifesciences, Pittsburgh, PA,
USA) [22]. Membranes were blocked with 5% non-fat dry milk in
0.1% Tween-TBS and incubated with the specific antibodies.
Mouse anti-b-actin was purchased from Santa Cruz Biotechnology
(California, USA). Rabbit anti-TGFb, anti-TGFb receptor II,
anti-Smad3 and horseradish peroxidase-conjugated goat anti-
rabbit IgG secondary antibody were purchased from Cell
Signaling (Beverly, MA, USA), and goat anti-mouse IgG
secondary antibody from GE Lifesciences (Pittsburgh, PA, USA).
The antibody-protein complex was detected using the ECL
Western Blotting Detection Reagents (GE Lifesciences).
HF treatment in an APL transplant model
To analyze in vivo effects of HF, irradiated immunodeficient
non-obese diabetic/severe combined immunodeficiency (NOD/
SCID) mice were injected with leukemic cells from hCG-PML-
RARa transgenic mice (TM). The TM were kindly provided by
Prof. Pier Paolo Pandolfi (Beth Israel Deaconess Medical Center,
Harvard Stem Cell Institute, Boston, MA, USA) and their
generation has been described elsewhere [23]. Notably, in this
transgenic model, a lethal form of leukemia that closely resembles
human APL occurs after a long pre-leukemic phase (12–15
months) and affects only 10–15% of the TM [24]. We have
established a transplant model, in which all animals develop
leukemia after 14 days from the transplant. Briefly, leukemic cells,
previously maintained at 280uC, were thawed and suspended in
RPMI 1640 with 10% FCS. After Trypan blue exclusion testing
and 12 hours after sublethal cobalt irradiation with 250 cGy,
2610
6 viable cells were intravenously injected into the ocular
plexus of CB17-Prkdc
scid/J 10- to 12-week-old NOD/SCID mice
(The Jackson Laboratory, Bar Harbor, Maine, USA). Animals
were maintained under pathogen-free conditions and received
autoclaved food and water ad libitum. Experiments were conducted
according to institutional and national guidelines for the care and
use of laboratory animals
The definition of the dose and mode of administration of HF
was based on previous reports of the in vivo use of the drug in solid
tumors and fibrosis models [14,15,17,25,26,27,28], and pilot
experiments were performed to confirm leukemic infiltration in
transplanted animals and to test the efficacy and toxicity of HF.
Twenty-four hours after the transplant procedure, NOD/SCID
mice received treatment with vehicle only (0.9% NaCl; n=5) or
150 mg/kg/day HF (n=5) as an intraperitoneal injection for 21
consecutive days. At the end of the experiment (day 21), mice were
sacrificed under ketamine anesthesia after being subjected to a
cardiac puncture to obtain peripheral blood (PB) samples. Non-
leukemic, age-matched NOD/SCID were used as controls (n=3).
Animals were maintained under pathogen-free conditions and
received autoclaved food and water ad libitum.
Analysis of the hematological and molecular responses
to HF in vivo
For monitoring PB counts, mice were bled from the tail before
transplantation and 10 days after the beginning of HF injections.
Automated counts (hemoglobin, white blood cells, and platelets)
were performed using a T-890 Coulter cell counter (Coulter
Corporation, Hialeah, FL, USA), and differential counts were
obtained from Leishman-Wright-Giemsa-stained smears. In addi-
tion, after euthanasia, bone marrow (BM) cells were obtained by
flushing the bone cavities of femurs and tibiae with RPMI 1640
containing 10% FCS. Cells were washed once, and then the pellet
was resuspended in PBS at a concentration of 10
6/mL.
Approximately 10
5 cells were used for cytospin slide preparation
and staining with Leishman-Wright-Giemsa, and then 10
6 cells
were used for DNA extraction and PCR analysis to detect PML-
RARa, as previously described by van Dongen [29].
For morphological analysis of PB and bone marrow slides, a
minimum of 100 PB and 200 BM cells were counted, and then
myeloid cells were classified as immature, intermediate, or mature,
according to the Bethesda proposals for classification of non-
lymphoid hematopoietic neoplasms in mice [30]. Because
extensive spleen infiltration was observed in leukemic animals,
the relation between the spleen and body weight was also assessed
to further quantify the hematological response to HF.
Quantification of TGFb in the serum of leukemic mice
treated with HF
Serum andBMsamplesoftransplantedand control NOD/SCID
mice were obtained after euthanasia, as previously described, and
used to quantify TGFb using the enzyme-linked immunosorbent
assay(ELISA).Serumsampleswerestocked at280uC untiluse.BM
cells werewashed twice with16PBSand total protein extracts were
prepared by suspending cell pellets in a lysis buffer (20 mM Tris
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 2.5 mM sodium pyrophosphate, and 1 mM PMSF)
supplementedwitha cocktail ofprotease and phosphataseinhibitors
(Sigma Aldrich), and then subjecting the samples to three cycles of
sonication. The resulting lysates were centrifuged at 13000 rpm for
10 minutes at 4uC, and then supernatants (a minimum total protein
of 1 mg) were stocked at 220uC until use. Subsequently, serum and
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26713Figure 1. Halofuginone (HF) exerts antiproliferative effects in acute promyelocytic leukemia (APL) cell lines NB4 and NB4-R2. (A)
Representative example of one out of three experiments of flow cytometric analysis of bromodeoxyuridine (BrdU; y-axis) and 7-amino-actinomycin
(7-AAD; x-axis) staining of NB4 cells incubated with increasing doses of HF or all-trans retinoic acid (ATRA, as a control), showing HF-induced growth
arrest at the G1/S transition. Cell subpopulations were identified as R1 (sub G0/G1, apoptotic cells), R2 (G0/G1), R3 (G2+M), and R4 (S phase). (B–C) Cell
cycle status of NB4 (B) and NB4-R2 (C) cells after treatment with increasing doses of HF and BrdU incorporation. Percentage of cells in S phase or
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immunoreactive TGFb by acidification, and then used in a
sandwich ELISA assay using the Quantikine TGFb1 Immunoassay
kit (R&D Systems, Minneapolis, MN, USA), according to the
manufacturer’s recommendations. The optical density was deter-
mined using a microplate reader set at an absorbance of 450 nm
and a standard curve was generated to report the results of TGFb
quantification in pg/mL.
Statistical analysis
The effects of HF on APL cell lines regarding cell proliferation,
apoptosis, BCL-2 expression, and transcription of TGFb target
genes were analyzed by multivariate analysis using the mixed
linear model. Comparisons simultaneously included the following
variables: treatment with variable doses of HF, cell type (either
NB4 or NB4-R2), and addition of TGFb. For in vivo experiments,
differences in blood cell counts, percentage of immature cells,
comparisons of the spleen/body weight ratio, and TGFb
quantification in leukemic and control mice were evaluated by
analysis of the variance (ANOVA) between groups followed by the
Bonferroni’s correction post-test. In all comparisons, a significance
level of P,0.05 was considered to be significant. Statistical
analyses were performed using SPSS 13.0 software.
Results
HF exerts anti-proliferative actions on APL
Cell cycle analysis, evaluated by the immunofluorescent
staining of incorporated BrdU and 7-AAD, showed that, in
both NB4 and NB4-R2 cell lines, HF inhibited cellular
proliferation (P,0.001) and induced apoptosis (P=0.002) in a
dose-dependent manner. Increasing doses of HF blocked cell
cycle progression at the G1/S transition (Fig. 1A–C and Figure
S1). In addition, doses greater than 35 ng/mL of halofuginone
also induced an accumulation of cells in G2+M. Notably, NB4-
R2 cells were more susceptible to HF than NB4 cells (P,0.001)
(Fig. 1A–C and Figure S1). Similar results were detected using
the Trypan blue exclusion test. Compared to control samples,
treatment with 50 ng/mL HF reduced NB4 cell viability by
44.3% (40–46.77%) and 70.5% (62.3–72.8%) after 24 and
48 hours of treatment, respectively. Indeed, no increase in
viable cells numbers was observed after 24 hours of treatment
with more than 50 ng/mL HF (Fig. 1D–E). Simultaneously,
doses of HF greater than 50 ng/mL induced initial and late-
stage apoptosis after 24 hours of treatment as determined by
Annexin V and PI binding assays and flow cytometric analysis
(P,0.001). In addition, after 48 hours of incubation, HF
induced a 1.6- and 2.5-fold increase in apoptosis at 100 and
200 ng/mL, respectively (Fig. 2A–B).
When TGFb was added to NB4 cell cultures with HF at
concentrations of 25–50 ng/mL, a significant increase (P,0.001)
in growth inhibition was observed, suggesting an additive effect
between the two molecules. At doses $100 ng/mL of HF, less
than 10% of the cells were in S phase, suggesting that a maximum
effect was reached (Fig. 3A). Regarding apoptosis, the effect of HF
was similar in the presence or absence of TGFb (Fig. 3B), except
for the treatment with 12.5 ng/mL of HF. Although the
multivariate analysis by the mixed linear model revealed that
apoptosis is identified by green or blue lines, respectively. Results confirmed that, in both cell lines, HF inhibited cell proliferation (P,0.001) and
caused apoptosis (P=0.002), although the pro-apoptotic effect in NB4 cells was visually less evident than the one observed in NB4-R2. (D–E) Analysis
of the number of viable NB4 cells by Trypan blue exclusion according to the incubation time (P,0.001) with various doses of HF (P,0.001), indicated
by the right-sided legend. Forty-eight hours after incubation with doses greater than 50 ng/mL of halofuginone, the number of viable NB4 cells
significantly reduced.
doi:10.1371/journal.pone.0026713.g001
Figure 2. Halofuginone (HF) induces apoptosis in a dose-dependent manner in acute promyelocytic leukemia (APL) cell line NB4. (A,
B) Analysis of the number of apoptotic NB4 cells by Annexin V and propidium iodide binding assay according to the incubation time (P,0.001) with
various doses of halofuginone (P,0.001), indicated by the right-sided legend. Apoptosis was more pronounced after the 48-hour treatment (A) and
occurred particularly when doses greater than 100 ng/mL were used (B).
doi:10.1371/journal.pone.0026713.g002
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this was due to the results detected with 12.5 ng/mL of HF.
The ED50 of HF for the inhibition of proliferation after 24 hours
of incubation was calculated based on the percentage of cells in S
phase. Without concomitant treatment with TGFb,t h eE D 50 of HF
was 18 ng/mL (95% confidence interval (95% CI): 15.5–20.8 ng/
mL; R
2: 0.99). In the presence of TGFb,t h eE D 50 was 10 ng/mL
(95% CI: 7.45–15.7 ng/mL; R
2: 0.98), thus corroborating the
potential additive anti-proliferative action of TGFb and HF.
Halofuginone up-regulates the expression of TGFb target
genes and TGFb protein
HF dose-dependent up-regulation of TGFb (P,0.001), TGFbRI
(P,0.001), SMAD3 (P,0.001), p15 (P,0.001), and p21 (P,0.001)
gene expression was detected after 72 hours of incubation. In
addition, treatment resulted in the down-regulation of MYC
(P,0.001) with concentrations higher than 25 ng/mL (Fig. 4A–F).
The expression of TGFb protein was evaluated by Western
blotting and HF induced a dose-dependent increase in TGFb,
TGFb receptor II and Smad3 expression in NB4 cells (Fig. 5).
To verify that these effects were caused by HF treatment and
not a late cellular response to cell growth inhibition, some genes
were selected for a 24-hour HF incubation and real time PCR
analysis, including the addition of exogenous TGFb to NB4
cultures. Consistent with the 72-hour treatment assay, after 24-
hour treatment, HF significantly induced the transcription of
TGFb target genes (TGFbRI and p21) and repressed MYC
expression in NB4, regardless of the addition of exogenous TGFb
(Fig. 6). Indeed, as analyzed using the mixed linear model, the
results were similar in the presence or absence of TGFb for
TGFbRI (P=0.699), SMAD3 (P=0.963), p21 (P=0.295), and MYC
(P=0.768).
HF demonstrates anti-leukemic effects in the in vivo
model of APL
Table 1 shows that HF treatment for 21 days resulted in an
increase to normal hemoglobin levels and platelet counts in
leukemic mice. The WBC was significantly lower in leukemic mice
treated with HF compared with untreated controls. However, the
cytomorphological analysis of Leishman-stained PB smears demon-
strated that HF treatment reduced the percentage of immature
cells in the bone marrow (66.3617.9% versus 2769.3%; P,0.01)
and peripheral blood samples (36.5621.04% versus 1565.09%;
P=0.06), although blasts were still detectable (Table 1). PML-
RARa detection by PCR confirmed the engraftment of leukemic
cells in all transplanted animals. As expected by the morphological
analysis of the bone marrow, samples obtained after treatment
tested positive for PML-RARa.
Since extensive spleen infiltration has been observed in the
hCG-PML-RARa mouse model [23], the relation between the
spleen and body weight was assessed to further quantify the
hematological response to HF. Compared with NOD/SCID wild-
type (WT) control mice, as expected, leukemic animals showed a
higher spleen/body weight ratio (P,0.001). Treatment with HF
resulted in a significant reduction of the spleen/body weight ratio
(P,0.05; Table 1). In addition, morphological analysis of Leishman-
stained slides of spleen imprints confirmed the infiltration of
immature cells resembling promyelocytes in leukemic animals and
demonstrated normal cellular distribution in the HF-treated mice.
HF reverses TGFb inhibition in PML-RARa leukemic mice
TGFb quantification in serum samples showed lower levels of
the cytokine in leukemic mice compared with WT controls
(P,0.0001). In animals that received HF treatment, TGFb levels
were similar to those in controls, suggesting that the drug could
reverse TGFb inhibition in PML-RARa leukemic mice. When
TGFb protein expression was verified in the bone marrow lysate, a
similar tendency of TGFb down-regulation in leukemic animals
was observed, although the data were not statistically significant
(Fig. 7).
Discussion
The present study demonstrates for the first time that HF has
anti-leukemic properties, reducing tumor growth and inducing
apoptosis in vitro and in vivo. A few studies have reported that HF
inhibits angiogenesis in vitro [31] and T cell activation [32], with
doses ranging from 5 to 400 ng/mL. Previous studies regarding
Figure 3. Treatment of APL cells with halofuginone (HF) results
in growth arrest (A) and apoptosis (B) regardless of TGFb
exogenous stimulus. Cell cycle effects were determined by the BrdU
incorporation assay. Continuous and dotted lines represent the effects of
HF in the absence or presence of exogenous TGFb in cell cultures,
respectively. The multivariate analysis by the mixed linear model revealed
that addition of TGFb is statistically relevant (P,0.001) for cell proliferation
and apoptosis (P=0.013). Regarding the latter, the percentage of
apoptotic cells was similar in samples treated with 25–200 ng/mL of HF
irrespective of TGFb addition. Therefore, the significant difference reflects
the results detected with 12.5 ng/mL of halofuginone. The effective dose
at 50% (ED50) of HF for the inhibition of proliferation was 18 ng/mL,
whereas,in the presenceof TGFb,t h eE D 50 was reducedto10 ng/mL, thus
suggesting a potential additive anti-proliferative action of TGFb and HF.
Data represent the results of three independent experiments.
doi:10.1371/journal.pone.0026713.g003
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of a 1.5-mg/kg dose in mice produced plasma concentrations
between 173 and 209 ng/mL at 10 minutes after administration,
with a 100% bioavailability and rapid distribution of the drug to
all tissues, except the brain. In addition, HF doses greater than
1.5 mg/kg proved excessively toxic to mice [33]. In vivo studies
using HF have reported significant anti-tumoral effects of the drug
with intraperitoneal doses varying from 50 to 300 mg/kg with no
Figure 4. Halofuginone (HF) induces activation of TGFb signaling in APL cell lines. (A–F) Real-time PCR analysis of TGFb and its target
genes in NB4 cells treated with increasing doses of HF, showing up-regulation of TGFb (A), TGFbRI (B), SMAD3 (C), p15 (D), p21 (E), and repression of
MYC (F).
doi:10.1371/journal.pone.0026713.g004
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in vitro and in vivo assays were within the range previously reported
to be effective and non-toxic. Importantly, HF has been previously
shown to reduce solid tumor growth, but no published data exist
on its actions in hematologic diseases.
HF exerted a potent anti-proliferative effect with an ED50 of
18 ng/mL (95% CI: 15.5–20.8 ng/mL), and was as effective in
NB4 as in NB4-R2 cells. HF-induced cell growth inhibition was
associated with dose-dependent up-regulation of TGFb target
genes. Treatment resulted in an increase in the number of TGFb
Figure 5. Halofuginone (HF) up-regulates the expression of TGFb, TGFb receptor II and Smad3 protein in the NB4 APL cell line.
Western blot analysis shows that increasing doses of HF (6.25–200 ng/mL) induced the expression of TGFb and its mediators after 72 hours of
incubation. CTRL: control.
doi:10.1371/journal.pone.0026713.g005
Figure 6. Halofuginone (HF) induces activation of TGFb signaling in APL cells regardless of exogenous TGFb addition. (A–D) Real-time
PCR analysis in the presence or absence of exogenous TGFb, showing similar effects of HF in NB4 cells: (A) TGFbRI (P=0.699); (B) SMAD3 (P=0.963); (C)
MYC (P=0.768), and (D) p21 (P=0.295).
doi:10.1371/journal.pone.0026713.g006
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consistent with the previously demonstrated positive feedback of
the pathway [34]. Moreover, the expression of other genes that
encode proteins of the TGFb pathway (including TGFbRI and
SMAD3) were modulated by HF treatment. SMAD3, when
phosphorylated and released from the receptor complex by
TGFbRI, forms a heterodimeric complex with SMAD4, which
then translocates to the nucleus to regulate transcription of target
genes. Consistent with the activation of the TGFb pathway
induced by HF, our results showed up-regulation of the cyclin-
dependent kinase inhibitors p15 and p21 and down-regulation of
MYC, which may have contributed to TGFb growth inhibition.
MYC appears to be a very specific target of TGFb because its
transcription is mediated by SMAD3 binding to a responsive
element in the promoter of the gene [35,36]. In addition, our
findings agree with the evidence that, upon TGFb stimulation,
down-regulation of MYC creates a positive feedback loop that
further amplifies p15 and p21 expression [1,2,37].
HF inhibited proliferation and induced apoptosis in the absence
of exogenous TGFb, but addition of the latter potentiated the
effects of HF and resulted in a reduction of the ED50 concentration
by 45% and further up-regulated the expression of TGFbRI,
SMAD3 and p21. Of note, as shown in figure 6, the addition of
TGFb alone to NB4 cells was able to up-regulate its target genes.
This can be attributed to the TGFb property of activating its own
mRNA expression and protein secretion. Therefore, one could
hypothesize that the up-regulation of TGFb target genes by HF
results from a combination of increased secretion of TGFb and a
direct effect of the drug on transcription.
The results obtained with HF treatment in a murine transplant
model of APL in NOD/SCID mice reinforced the potential anti-
leukemic effects of the drug. Mice transplanted with PML-RARa
cells and treated with HF presented hematological remission in
peripheral blood, bone marrow, and spleen as determined by
blood cell counts and cytological analysis. HF did not induce
differentiation of leukemic blasts, and the improvement of
hematopoiesis resulted from the decrease of the leukemic burden.
In addition, consistent with the evidence of the downregulation
of TGFb signaling in APL, TGFb protein levels were decreased in
leukemic PML-RARa animals and HF increased TGFb levels to
values very similar to those of control non-leukemic mice. The
partial hematological remission observed in HF-treated animals
may be associated with the direct induction of the cytokine TGFb
itself, known to play a key role in the regulation of human
hematopoietic stem cell quiescence, proliferation and differentia-
tion [38]. Although the effect of TGFb as a potent negative
regulator of hematopoieses may contribute to tumor control, its
role in leukemogenesis has been more recently associated with the
findings of disruption in TGFb signaling either by mutational
inactivation or down-regulation of its components [13]. Therefore,
we have attributed the TGFb-dependent growth inhibitory effects
of HF to the indirect transcription regulation of cell cycle target
genes.
In contrast to our findings, previous studies of fibrosis models
have shown that HF inhibits TGFb-induced phosphorylation of
Table 1. Peripheral blood cell counts, percentage of
immature cells, and spleen/body weight ratio of wild-type
control mice (WT; n=3) and NOD/SCID leukemic mice that
were treated with halofuginone (HF) (LEUK-HF; n=5) or left
untreated (LEUK; n=5).
WT LEUK LEUK-HF
Hb (g/dL) 15.360.6 9.661.67 12.061.40
*
WBC (610
3/mL) 2.3360.57 20.6621.9 4.263.89
**
Platelets (610
3/mL) 1160.06215.9 552683.2 932.06122.5
***
PB blasts (%) 3.661.52 36.5621.04 15.065.09
{
BM blasts (%) - 66.3617.9 2769.3
{
Spleen/body weight ratio 0.00360.0002 0.01260.004 0.00660.001
Immunodeficient NOD/SCID mice were injected with leukemic cells from hCG-
PML-RARa transgenic mice after sublethal irradiation and, 24 hours later, were
treated with vehicle (LEUK; n=5)or150mg/kg HF (LEUK-HF; n=5)asan
intraperitoneal injection for 21 consecutive days. HF treatment resulted in the
reduction of white blood cell counts (WBC), increase in hemoglobin (Hb) levels
and platelets count to normal values, reduction of the blast percentage in
peripheral blood (PB) and bone marrow (BM), and reduction of the spleen size
in leukemic transplanted animals. Results are shown as average values 6
standard deviation. The differences of cell counts in leukemic animals treated
with HF or not was significant, when analyzed by ANOVA and Bonferroni’s post
test (
*P,0.05,
**P,0.01,
***P,0.001,
{P,0.01 for Hb, WBC, platelets and PB/BM
blasts, respectively).
doi:10.1371/journal.pone.0026713.t001
Figure 7. TGFb quantification in serum (A) and bone marrow (B) of leukemic NOD/SCID mice treated with halofuginone (HF). As
determined by enzyme-linked immunosorbent assay, TGFb serum levels were lower in leukemic transplanted mice (LEUK) compared with wild-type
(WT) controls (P,0.001), and HF increased TGFb to levels similar to those in controls.
doi:10.1371/journal.pone.0026713.g007
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This may be explained by the fact that TGFb functions are both
cell type- and context-dependent. In tumorigenesis, it can switch
from tumor suppressor in the premalignant stages to prooncogene
at later stages of the disease. We believe that malignant cells of
APL have decreased or altered TGFb-responsiveness and that HF
was able to restore TGFb signaling activation.
Of interest, it has been shown that low doses of HF selectively
inhibited the differentiation of the proinflammatory T helper 17
murine and human cells (TH17 cells) by activating a cytoprotec-
tive signaling pathway, without directly modulating TGFb-
induced SMAD2 phosphorylation or other lymphocytes responses
to TGFb [41]. Indeed, Wu et al demonstrated that TH17 cells and
interleukin-17 concentrations were significantly increased in
peripheral blood samples from AML patients when compared
with those from healthy volunteers, suggesting that TH17 cells
may play a role in leukemogenesis [42]. Although not dependent
on TGFb regulation, this effect strengthens the potential of HF as
an anti-leukemic drug.
Recent evidence has suggested that deregulation of the TGFb
pathway may play a role in APL pathogenesis. PML-RARa may
interrupt the interaction of nuclear PML with the SMAD2/3/4
complex, leading to blockade of TGFb transcriptional activity
[13]. In this context, considering the effects on TGFb target gene
expression, HF could reverse this blockade and prevent cell
proliferation in an in vitro model of APL. Consistent with the
hypothesis of TGFb blockade in APL, our results did not show
significant differences in cell growth inhibition and apoptosis when
NB4 and NB4 cells treated with TGFb were compared, suggesting
that APL cells are resistant to the anti-proliferative effects of this
cytokine.
We can hypothesize that although the disruption of the TGFb
pathway itself is not sufficient to initiate malignant transformation,
the loss of the TGFb response may be a critical second step that
contributes to leukemia progression. In this context, the modula-
tion of TGFb signaling may have therapeutic interest in APL.
Supporting Information
Figure S1 Cell cycle status of NB4 and NB4-R2 cells
after treatment with increasing doses of halofuginone.
Cell cycle status according to BrdU incorporation by NB4 (upper
graphic) and NB4-R2 (lower graphic) cells after treatment with
increasing doses of halofuginone. The multivariate analysis using
the mixed linear model confirmed that, in both cell lines, the drug
inhibited cell proliferation (P,0.001) and caused apoptosis
(P=0.002), although the pro-apoptotic effect in NB4 cells was
visually less evident than the one observed in NB4-R2.
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